source
- AstraZeneca acquires Omniose to boost bacterial vaccine capabilitiesAstraZeneca has completed the purchase of Omniose, a specialist in vaccine bioconjugation, making the company a wholly owned subsidiary of its infectious disease division. The two firms began coll…
- Valneva's Shigella vaccine cuts infection rates in phase 2 trialValneva reported that its Shigella vaccine reduced the number of intestinal infections in a phase 2 controlled human infection model study conducted in the United States. The trial enrolled 120 he…